Contact Information
David Colcher, Ph.D.
  • Deputy Director, Radioimmunotherapy
  • Professor, Immunology
  • Director, Small Animal Imaging Core

Languages Spoken
  • English


Dr. Colcher has 20 years of experience using radiolabeled mAbs both in vitro and in vivo in model systems and in numerous clinical studies. He developed a number of antibodies to tumor associated antigens that are well recognized in the field.

Professional Experience

  • 2014 - present, Deputy Director, Division of Radioimmunotherapy and Professor, Department of Immunology, Beckman Research Institute of City of Hope, Duarte, CA
  • 2002 - 2014, Deputy Director, Division of Radioimmunotherapy and Professor, Department of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute of City of Hope, Duarte, CA
  • 2001 - 2002, Corixa Fellow, Radioimmunotherapy, Corixa Corp, South San Francisco, CA
  • 2000 - 2001, Director, Radioimmunotherapy Research, Corixa Corp, South San Francisco, CA
  • 1999 - 2000, Director, Radioimmunotherapy Research, Coulter Pharmaceutical. Inc., South San Francisco, CA
  • 1991 - 1999, Professor, Eppley Institute for Research in Cancer and Allied Diseases, and Department of Radiology, University of Nebraska Medical Center
  • 1990 - 1999, Professor, and Director, Antibody Labeling Facility, Department of Pathology and Microbiology, University of Nebraska Medical Center
  • 1984 - 1990, Supervisory Microbiologist, Laboratory of Tumor Immunology and Biology, DCBDC, NCI, NIH, Bethesda, MD
  • 1982 - 1984, Research Microbiologist, Laboratory of Tumor Immunology and Biology, DCBD, NCI, NIH, Bethesda, MD
  • 1980 - 1982, Microbiologist, Laboratory of Cellular and Molecular Biology, DCCP, NCI, NIH, Bethesda, MD
  • 1978, International Association of Breast Cancer Research
  • 1977 - 1980, Senior Staff Fellow, Tumor Virus Detection Section, DCCP, NCI, NIH, Bethesda, MD
  • 1977, Member, National Cancer Institute Breast Cancer Task Force
  • 1977, National Institutes of Health Predoctoral Fellowship
  • 1976, National Institutes of Health Research Trainee
  • 1973-1977, Scientist, Meloy Laboratories, Inc, Springfield, VA


  • 1974, Columbia University, Institute of Cancer Research, Dept. of Human Genetics & Development, N.Y., N.Y., Ph.D., Retrovirology & Immunology
  • 1974, Columbia University, Institute of Cancer Research, Dept. of Human Genetics & Development, N.Y, N.Y., M.Ph., Retrovirology & Immunology
  • 1971, Massachusetts Institute of Technology, Department of Life Sciences, Cambridge, Massachusetts, S.B.L.S., Biology


  • 1985, United States Department of Commerce Inventor’s Award for: “Contributions through the Creative Invention of Monoclonal Antibodies Reactive with Human Breast Cancer”


  • European Association for Nuclear Medicine
  • Society of Molecular Imaging
  • The Society of Nuclear Medicine
  • American Association for Cancer Research
  • American Association for the Advancement of Science


  • Yazaki PJ, Kassa T, Cheung CW, Crow DM, Sherman MA, Bading JR, Anderson AL, Colcher D, Raubitschek A. Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol.;35: 151-8,2008. PMID: 18312824 [PubMed - indexed for MEDLlNE]
  • Johnson EE, Lum HD, Rakhmilevich AL, Schmidt BE, Furlong M, Buhtoiarov IN, Hank JA, Raubitschek A, Colcher D, Reisfeld RA, Gillies SD, Sondel PM. Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol Immunother. 2008 Apr 26. [Epub ahead of print] PMID: 18438664 [PubMed - as supplied by publisher]
  • Li, L., Yazaki, P.J., Anderson, A.L., Crow, D., Colcher, D., Wu, A.M., Williams, L.E., Wong, J.Y., Raubitschek, A., and Shively, J.E.: Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjug Chem. 17:68-76, 2006.
  • Crow, D.M., Williams, L., Colcher, D., Wong, J.Y., Raubitschek, A., and Shively, J.E.: Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. Bioconjug Chem. 16:1117-25, 2005.
  • Chauhan, S.C., Jain, M., Moore, E.D., Wittel, U.A., Li, J., Gwilt, P.R., Colcher, D., and Batra, S.K.: Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imaging 32:264-73, 2005.
  • Kenanova, V., Olafsen, T., Crow, D.M., Sundaresan, G., Subbarayan, M., Carter, N.H., Ikle, D.N., Yazaki, P.J., Chatziioannou, A.F., Gambhir, S.S., Williams, L.E., Shively, J.E., Colcher, D., Raubitschek, A.A., and Wu, A.M.: Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 65:622-31, 2005.
  • Wong, J.Y., Chu, D.Z., Williams, L.E., Yamauchi, D.M., Ikle, D.N., Kwok, C.S., Liu, A., Wilczynski, S., Colcher, D., Yazaki, P.J., Shively, J.E., Wu, A.M., Raubitschek, A.A.: Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anti-carcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res. 10:5014-5021, 2004.
  • Augustine SC, Norenberg, JP Colcher DM, Vose JM, Gobar L.S, Dukat VJ, Hohenstein MA, Rutar FJ, Jacobson DA, Tempero MA: Combination therapy for Non-Hodgkin's lymphoma: An opportunity for pharmaceutical care in a specialty practice. J. Am. Pharm. Assoc. 42: 93-100, 2002.
  • Cardarelli PM, Quinn, M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G: Binding to CD20 by Anti-B1 Antibody or F(ab’) 2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immuno. Immunotherapy 51: 15-24, 2002.
  • Milenic DE, Roselli M, Mirzadeh S, Pippin CG, Gansow OA, Colcher D, Brechbiel MW, Schlom, J: In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biother. Radiopharm. 16: 133-146, 2001.
  • Goel A, Augustine S, Baranowska-Kortylewicz J, Colcher D, Booth BJM, Pavlinkova G, Tempero M, Batra SK: Single-dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain Fvs. Clinical Cancer Res. 7: 175-184, 2001.
  • Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D: High dose therapy with 90Yttrium labeled monoclonal antibody CC49: A phase I trial. Clin. Cancer Res. 6: 3095-3102, 2000
  • Pavlinkova G, Booth BJ, Batra SK, Colcher D: Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. Clin. Cancer Res. 5: 2613-2619, 1999.
  • Colcher D, Goel A, Pavlinkova G, Beresford G, Booth B, Batra SK: Effects of genetic engineering on the pharmacokinetics of antibodies. Q. J. Nucl. Med. 43: 132-139, 1999.
  • Colcher D, Pavlinkova G, Beresford G, Booth BJ, Batra SK: Single-chain antibodies in pancreatic cancer. Ann. N.Y. Acad. Sci. 880: 263-280, 1999.
  • Pavlinkova G, Beresford G, Booth, BJM, Batra SK, Colcher D: Charge-modified single chain antibody constructs of monoclonal antibody CC49: Generation, characterization, pharmacokinetics, and biodistribution analysis. J. Nuclear Med. Bio. 26: 27-34, 1999.
  • Colcher D, Pavlinkova G, Beresford G, Booth BJM, Choudhury A, Batra SK: Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q.J. Nuclear Med. 42: 225-241, 1998.
  • Milenic DE, Roselli M, Brechbiel MW, Pippin CG, McMurray TJ, Carrasquillo JA, Colcher D, Lambrecht R, Gansow OA, Schlom J: In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand. Eur. J. Nuclear Med. 25: 471-480, 1998.
  • Colcher D: Centralized radiolabeling of antibodies for radioimmunotherapy. J. Nuclear Med. 39: 11S-13S, 1998.
  • Leichner PK, Akabani G, Colcher D, Harrison KA, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Tempero, MA: Patient-specific dosimetry of indium‑111/yttrium-90-labeled monoclonal antibody CC49. J.Nuclear Med. 38: 512-516, 1997.
  • Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlom J, Wisecarver J, Colcher D: High dose therapy with 131I labeled monoclonal antibody CC49: A phase I trial. J. Clin. Oncol. 15: 1518-1528, 1997.
  • Kawatsu, R, Sanderson SD, Blanco I, Kendall N, Taylor SM, Colcher D: Conformationally biased analogues of human C5a mediate changes in vascular permeability. J. of Pharm. and Exp. Therapeutics. 278:432-440, 1996.
  • Tempero M, Colcher D: An overview of monoclonal based therapy in pancreatic cancer. Int J Pancreatology. 16:300-302, 1994.
  • Remmenga SW, Colcher D, Gansow O, Pippen CG, Raubitschek A: Continuous infusion chemotherapy as a radiation-enhancing agent for yttrium-90-radiolabeled monoclonal antibody therapy of a human tumor xenograft. Gynecol Oncol. 55: 115-22, 1994.
  • Nieroda CA, Milenic DE, Colcher D, Schlom, J: Monoclonal antibodies for use in radioimmunoguided surgery (RIGS). In Martin, EW, Jr. (Ed.): Medical Intelligence Unit: Radioimmunoguided Surgery (RIGS) in the Detection and Treatment of Colorectal Cancer. Austin, R.G. Landes Company, 1994, pp 7-27.
  • Schott ME, Schlom J, Siler K, Milenic DE, Eggensperger D, Colcher D, Cheng R, Kruper WJ, Fordyce W, Goeckeler W: Biodistribution and pre-clinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. Cancer 73: 993-998, 1994.
  • Schlom J, Eggensperger D, Colcher D, Molinolo A, Houchens D, Miller LS, Hinkle G, Siler K: Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 52: 1067-1072, 1992.


  • City of Hope - Main Campus (Duarte)
    1500 East Duarte Road
    Duarte, CA 91010